VivoSim Labs, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VIVS | EOCN | VIVOBIOT.BO | 18H0.F | PCSA | EVGN | |
|---|---|---|---|---|---|---|
| Market cap | 2.52M | 2.96M | 328.87M | 5.11M | 5.41M | 6.41M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | — | — | -0.5 | -0.6 |
| Price/book | -0.2 | 0.2 | 0.3 | -1.1 | -17.0 | -1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −93.86% | −71.44% | −58.81% | −25.00% | −75.51% | −68.97% |
| Today | +5.99% | −1.42% | +6.77% | −23.81% | −0.26% | +1.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VIVS news ›Overview of 3D in vitro models for studying TME interactions (IMAGE)
(A) Modeling tumor-stroma interactions of the TME in organoid cocultures. (B) Modeling tumor-immune interactions in organoid cocultures for evaluating immunotherapeutic drugs. (C) Modeling vascularized organoids and perfusion using…
VIVA In Vitro Diagnostics and ASKA Biotech Announce Strategic Partnership to Advance VIVA-ELISA® Industrialization
The Spanish biotechnology company and German CDMO join forces to advance the development and manufacturing of VIVA-ELISA®, targeting its first Research Use Only (RUO) product in Q2 2027. The agreement strengthens VIVA's transition from…
Vitroscope raises US$7m to study drugs in living tissue
The Norwegian biotechnology company secured US$5m in seed financing and US$2m in non-dilutive funding, which does not require issuing additional shares. The investment will support the commercial rollout of vitro.alive, a laboratory…
Vitroscope raises $7M to turn living human tissue into a new source of drug discovery data
Vitroscope, a biotech company developing perfusion platforms to study immune activity, treatment responses and disease mechanisms in real time, has raised $7 million, comprising a $5 million seed round and $2 million in non-dilutive…
VivoSim and Chemveda partner to rapidly test AI-designed drug candidates in human tissue models.
VivoSim Labs and Chemveda Life Sciences have formed a strategic collaboration to accelerate drug discovery by testing AI-designed drug compounds using VivoSim's 3D human liver and intestine tissue models. This partnership aims to quickly…
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
The new data strengthens VivoSim's positioning in the growing market for human-relevant predictive toxicology and New Approach Methodologies (NAMs), as pharmaceutical companies increasingly look for better ways to identify safety risks…
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New A... VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing…
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced…
Semi-automated motility assay speeds the hunt for new liver fluke drugs
A new semi-automated imaging assay that monitors the motility of Fasciola hepatica juveniles identified three nanomolar-potent salicylanilide hits, though only triclabendazole proved parasiticidal within 72 hours. Only TCBZ displayed…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- stocktitan.net2
- defenseworld.net1
- greatreporter.com1
- htworld.co.uk1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.